All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Surgery for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life Mean AcroQoL score (0‐100) · adults with growth‐hormone secreting pituitary adenomas
Surgery alone showed no clear difference in health‐related quality of life Mean AcroQoL score (0‐100) compared with pharmacological therapy alone (low certainty).
1 finding from 1 review
Disease‐related complications Intubation difficulties requiring postponement of surgery · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes disease‐related complications Intubation difficulties requiring… compared with preoperative pharmacological therapy and surgery (very low certainty).
1 finding from 1 review
Recurrence · adults with growth‐hormone secreting pituitary adenomas
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people with inhibitors
1 finding from 1 review
QoL · people with inhibitors
1 finding from 1 review
Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR), All bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people with inhibitors
1 finding from 1 review
Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis may leads to higher proportion with zero bleeds compared with on‐demand therapy (low certainty).
1 finding from 1 review
Change from baseline in SF‐36v2 ‐ mental component scoreScale from: 0 to 100 (better) · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Adverse events ‐ All adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ All adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review